According to FutureWise analysis, the Alzheimer’s disease diagnostic market is expected to reach US$10.86 billion by 2031, growing at a CAGR of 5.28%. The Alzheimer's disease diagnostic market is witnessing steady growth driven by the rising global prevalence of dementia and increasing awareness about early detection. Advancements in biomarker-based diagnostics, neuroimaging technologies, and AI-enabled cognitive assessment tools are enhancing diagnostic accuracy and speed. Additionally, increased R&D investments and supportive healthcare policies are accelerating the adoption of innovative diagnostic solutions.
Alzheimer's is a neurodegenerative disease that starts with minor memory loss and gradually becomes more severe over time. It usually starts with minor memory loss and progresses to the loss of social interaction and communication skills. It is an incurable disease with a long preclinical period and a progressive course. It can significantly impact an individual’s ability to perform daily activities. In most individuals with the disease, symptoms typically first appear in their mid-60s. Early-onset Alzheimer's is rare and occurs between an individual's 30s and mid-60s. Alzheimer's disease is the most common type of dementia among older adults.
A diagnosis of Alzheimer's disease cannot be determined through a single test, as it requires a comprehensive evaluation to identify specific symptoms and rule out other potential causes of dementia. The process involves a careful medical assessment, which includes obtaining a detailed medical history, conducting mental status testing, performing a thorough physical and neurological examination, and administering blood tests. Brain imaging exams, such as CT scans, PET and MRI, also play a crucial role in the diagnostic process. Computed tomography (CT) head imaging is used to examine the brain for any other potential causes of dementia, such as brain tumors, subdural hematomas, or strokes. On the other hand, MRI uses strong radio frequency pulses, magnetic fields, and a computer to make detailed images of internal body structures, including the brain. MRI can detect brain abnormalities related to mild cognitive impairment (MCI) and may even predict the likelihood of MCI progressing to Alzheimer's.
FutureWise Market Research has published a report that provides an insightful analysis alzheimer’s disease diagnostic market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, alzheimer’s disease diagnostic market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.